Cite

HARVARD Citation

    Shen, J. et al. (n.d.). FRI0322 Rationale for the atacicept dose for a phase iii study in patients with highly active and auto-antibody positive sle. Annals of the rheumatic diseases. p. 697. [Online]. 
  
Back to record